Analyst Reco. Regeneron Pharmaceuticals, Inc.

Equities

REGN

US75886F1075

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-10 pm EDT			5-day change	1st Jan Change
973.8 ^USD	+0.60%		+1.76%	+10.87%

May. 08	Regeneron Pharmaceuticals, Inc. Announces Latest DB-OTO Results Show Dramatically Improved Hearing to Normal Levels in a Child with Profound Genetic Deafness Within 24 Weeks and Initial Hearing Improvements in a Second Child at 6 Weeks	CI
May. 07	UBS Raises Regeneron Pharmaceuticals Price Target to $1,124 From $1,099, Maintains Buy Rating	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

UBS Raises Regeneron Pharmaceuticals Price Target to $1,124 From $1,099, Maintains Buy Rating	May. 07	MT
Deutsche Bank Adjusts Price Target on Regeneron Pharmaceuticals to $870 From $880, Hold Rating Kept	May. 03	MT
Goldman Sachs Adjusts Price Target on Regeneron Pharmaceuticals to $1,180 From $1,126	May. 03	MT
Morgan Stanley Raises Price Target on Regeneron Pharmaceuticals to $1,183 From $1,177	May. 02	MT
Piper Sandler Adjusts Regeneron Pharmaceuticals' Price Target to $1,000.25 From $1,016	May. 02	MT
RBC Cuts Price Target on Regeneron Pharmaceuticals to $1,185 From $1,189	May. 02	MT
Oppenheimer Adjusts Price Target on Regeneron Pharmaceuticals to $1,175 From $1,125	Apr. 26	MT
TD Cowen Adjusts Regeneron Pharmaceuticals' Price Target to $1,030 From $1,020, Keeps Buy Rating	Apr. 24	MT
UBS Adjusts Regeneron Pharmaceuticals Price Target to $1,099 From $1,090, Maintains Buy Rating	Apr. 17	MT
ANALYST RECOMMENDATIONS : Las Vegas Sands, Regeneron, Kinder Morgan, Rivian, Royal Caribbean...	Apr. 17
Goldman Sachs Adjusts Regeneron Pharmaceuticals Price Target to $1,126 From $1,121, Buy Rating Kept	Apr. 15	MT
Morgan Stanley Raises Price Target on Regeneron Pharmaceuticals to $1,177 From $1,115, Keeps Overweight Rating	Apr. 09	MT
Intellia Therapeutics Ends Development Agreement With Regeneron Pharmaceuticals	Mar. 25	MT
Intellia Therapeutics Ends Development Agreement With Regeneron Pharmaceuticals	Mar. 22	MT
Intellia Therapeutics Ends Co-Development Agreement With Regeneron	Mar. 22	DJ
Morgan Stanley Raises Price Target on Regeneron Pharmaceuticals to $1,115 From $1,104, Maintains Overweight Rating	Mar. 13	MT
RBC Raises Price Target on Regeneron Pharmaceuticals to $1,184 From $1,096, Keeps Outperform Rating	Feb. 27	MT
RBC Trims Price Target on Regeneron Pharmaceuticals to $1,096 From $1,110, Keeps Outperform Rating	Feb. 22	MT
Cantor Fitzgerald Adjusts Price Target on Regeneron Pharmaceuticals to $925 From $850, Keeps Neutral Rating	Feb. 06	MT
UBS Adjusts Price Target on Regeneron Pharmaceuticals to $1,090 from $1,112, Maintains Buy Rating	Feb. 06	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Regeneron Pharmaceuticals, Inc.

Equities

REGN

US75886F1075

Analyst Reco.

Filters